| BIOGEN INC. DL -,0005 | 224.850 / -1.40% |
| Date/Time | 10/20 / 17:01 |
| Chg. / Chg.(%) | -3.200 / -1.40% |
| Bid | 225.500 / 225 |
| Ask | 225.850 / 225 |
| Open | 229.950 |
| Previous Close | 228.050 |
| High | 231.100 |
| Low | 224.850 |
| Volume [EUR] | 143,298.100 |
| Volume [Units] | 630 |
| Price fixings | 31 |
| ISIN | US09062X1037 |
| Security | IDP |
| Exchange | TradeGate |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| NASDAQ | 267.2000 |  |
216,933 |
| Cboe US | 267.25 | |
16,475 |
| IEX | 267.11 | |
16,055 |
| Xetra | 226.35 |  |
1,014 |
| TradeGate | 224.850 | |
630 |
| London Inter.. | 267.21 | |
382 |
| Vienna Globa.. | 229.00 | |
109 |
| Stuttgart | 227.350 | |
45 |
| gettex | 227.750 | |
6 |
| Berlin | 226.80 | |
4 |
| München | 227.65 | |
0 |
| Hamburg | 227.45 | |
0 |
| Düsseldorf | 226.85 | |
0 |
| Frankfurt | 227.5500 | |
0 |
| Hannover | 227.45 | |
0 |
| Lang & Schwa.. | 225.850 | |
|
| Mexico | 5,815.00 | |
54 |
| SIX Swiss Ex.. | 232.00 |
News
- Samsung Bioepis and Biogen Announce EMA Filing Acceptance of SB11, a Proposed Biosimilar Referencing Lucentis® (ranibizumab)
10/06/2020 / 13:00 - GlobeNewswire - Biogen to Invest $250 Million in a 20-year Initiative to Eliminate its Use of Fossil Fuels and Improve Public Health
09/14/2020 / 13:30 - GlobeNewswire - New Data at ACTRIMS-ECTRIMS Meeting Showcase Safety and Efficacy of Biogen’s Industry-Leading MS Portfolio
09/11/2020 / 14:01 - GlobeNewswire - New Biogen Data Presented at ACTRIMS-ECTRIMS Advance Understanding of Clinical and Health Disparities in MS
09/08/2020 / 13:30 - GlobeNewswire - FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review
08/07/2020 / 13:30 - GlobeNewswire
Personal area
Real-timeClick on 
to activate push quotes.
to activate push quotes.